Want to see FR:ABNX full AI Analyst Report?
Top Page
ABIONYX Pharma SA
(ABNX)
Select Model
Select Model
Rating:43Neutral
Price Target:
€1.50
▼(-25.00% Downside)
Action:Reiterated
Date:09/18/26
The score is primarily held down by weak financial performance—persistent large losses, ongoing cash burn, and rising leverage with declining equity. Technical indicators are neutral-to-soft (negative MACD and price below longer-term averages), offering limited support. Valuation is also constrained by a negative P/E and no dividend yield data.
Positive Factors
Specialized apoA-I/HDL platform
A focused platform built around apoA-I and HDL biology gives ABIONYX a coherent scientific identity and supports development across serious inflammatory and infectious indications. If clinical evidence continues to validate the approach, the platform could create multiple opportunities from related biological mechanisms.
Negative Factors
Persistent severe operating losses
Operating losses are extremely large relative to revenue, with a 2025 EBIT margin near negative 154% and continued negative net results. This demonstrates that the current business model has not reached operating leverage, making sustainable profitability dependent on materially higher revenue or a significant cost-structure improvement.
Read all positive and negative factors
Positive Factors
Negative Factors
Specialized apoA-I/HDL platform
A focused platform built around apoA-I and HDL biology gives ABIONYX a coherent scientific identity and supports development across serious inflammatory and infectious indications. If clinical evidence continues to validate the approach, the platform could create multiple opportunities from related biological mechanisms.
Read all positive factors
ABIONYX Pharma SA (ABNX) vs. iShares MSCI France ETF (EWQ)
Market Cap
€74.31M
Dividend YieldN/A
Average Volume (3M)167.13K
Price to Earnings (P/E)―
Beta (1Y)-0.21
Revenue Growth-10.38%
EPS Growth-72.05%
CountryFR
Employees49
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.22
Shares Outstanding43,736,416
10 Day Avg. Volume142,986
30 Day Avg. Volume167,126
Financial Highlights & Ratios
PEG Ratio-1.03
Price to Book (P/B)31.58
Price to Sales (P/S)33.12
P/FCF Ratio-42.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.39
Revenue Forecast (FY)€4.66M
ABIONYX Pharma SA Business Overview & Revenue Model
Company Description
ABIONYX Pharma SA is a biotechnology company dedicated to the identification and advancement of therapies for conditions affecting the kidneys and eyes. The firm's pipeline includes CER-001, an innovative negatively-charged lipoprotein particle. T...
How the Company Makes Money
ABIONYX Pharma SA primarily aims to generate revenue through the development and eventual commercialization (directly or via partners) of its drug candidates; however, specific, current revenue streams and amounts (e.g., product sales, licensing i...
ABIONYX Pharma SA Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
45
Neutral
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.88M | 4.06M | 4.60M | 4.64M | 5.25M | 675.00K |
| Gross Profit | 209.00K | 376.00K | 844.00K | 618.00K | 636.00K | 259.00K |
| EBITDA | -5.65M | -5.70M | -4.93M | -4.53M | -4.01M | -7.42M |
| Net Income | -8.06M | -5.55M | -4.40M | -3.52M | -4.21M | -5.82M |
Balance Sheet | ||||||
| Total Assets | 36.54M | 12.86M | 13.45M | 14.83M | 15.82M | 21.83M |
| Cash, Cash Equivalents and Short-Term Investments | 26.87M | 3.52M | 3.23M | 4.10M | 4.05M | 7.93M |
| Total Debt | 15.18M | 3.81M | 3.10M | 3.39M | 4.01M | 4.96M |
| Total Liabilities | 20.86M | 8.60M | 6.03M | 6.91M | 8.65M | 11.15M |
| Stockholders Equity | 15.68M | 4.26M | 7.42M | 7.92M | 7.17M | 10.68M |
Cash Flow | ||||||
| Free Cash Flow | -3.41M | -3.17M | -3.60M | -3.83M | -3.53M | -6.86M |
| Operating Cash Flow | -3.28M | -2.93M | -3.60M | -3.70M | -3.36M | -6.69M |
| Investing Cash Flow | -94.00K | -205.00K | -100.00K | -130.00K | -175.00K | 1.34M |
| Financing Cash Flow | 26.87M | 3.42M | 2.80M | 3.89M | -194.00K | 3.97M |
ABIONYX Pharma SA Technical Analysis
Negative
2.00
Price Trends
1.89
Negative
2.18
Negative
2.85
Negative
Market Momentum
-0.04
Positive
39.18
Neutral
10.05
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ABNX, the sentiment is Negative. The current price of 2 is above the 20-day moving average (MA) of 1.81, above the 50-day MA of 1.89, and below the 200-day MA of 2.85, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 39.18 is Neutral, neither overbought nor oversold. The STOCH value of 10.05 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ABNX.
ABIONYX Pharma SA Peers Comparison
UnderperformOutperform
Sector (55)
FR:ABNX
ABIONYX Pharma SA
1.62
-1.76
-52.04%
FR:ALCOX
Nicox SA
0.32
-0.05
-13.24%
FR:SIGHT
GenSight Biologics SA
0.08
-0.08
-47.47%
FR:ALSEN
Sensorion SAS
6.61
-11.99
-64.46%
ABIONYX Pharma SA Corporate Events
ABIONYX Pharma Updates Voting Rights as It Advances Sepsis-Focused Biotherapies
Oct 2, 2026
ABIONYX Pharma, a biopharmaceutical company focused on sepsis and critical care, develops apoA-I-based biologics and HDL carriers to address immune-inflammatory dysregulation in severe diseases where effective treatments are lacking. Backed by str...
ABIONYX Pharma trims bond debt with share-backed repayment, keeps cash runway to 2028
Oct 2, 2026
ABIONYX Pharma has partially repaid €1.75 million of its bond financing with Fenja Capital II A/S, settling about 70% in cash and 30% through a reserved capital increase of €0.52 million via the issuance of 331,299 new shares. The new ...
ABIONYX bolsters cash to €26.9m as losses deepen and sepsis strategy advances
Sep 23, 2026
ABIONYX Pharma reported first-half 2026 consolidated revenue of €1.9 million, generated entirely by its IRIS Pharma ophthalmology CRO unit, while its sepsis and LCAT deficiency programs remain pre-revenue and continue to supply bioproducts f...
ABIONYX Pharma Taps TEXCELL to Advance Viral Safety and Industrialization of CER-001
Sep 10, 2026
ABIONYX Pharma has entered a strategic partnership with TEXCELL, a division of ABL Diagnostics, to conduct viral safety and clearance studies for CER-001 as it prepares validation batches of its bioproduction process in France. The work is central...
ABIONYX Pharma Updates Share Capital and Voting Rights Structure
Sep 7, 2026
ABIONYX Pharma reported that as of August 31, 2026, its outstanding share capital stood at 43,736,415 shares, corresponding to 55,932,492 gross voting rights and 55,705,013 net voting rights. The disclosure, made in line with AMF regulations on vo...
ABIONYX Pharma Posts €1.9 Million H1 Revenue and Extends Cash Runway to 2028
Aug 27, 2026
ABIONYX Pharma reported consolidated half-year revenue of €1.9 million at the end of June 2026, entirely driven by its ophthalmology CRO unit IRIS Pharma, with biotech operations recording no sales as the company continues supplying its biop...
ABIONYX Pharma Updates Share Capital and Voting Rights Structure
Aug 4, 2026
ABIONYX Pharma has disclosed its latest capital and voting rights structure, reporting 42,568,071 shares in circulation as of July 31, 2026, corresponding to 54,764,148 gross voting rights and 54,519,932 net voting rights. The publication distingu...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.